Results 1 to 10 of about 72,842 (263)

Alemtuzumab in allogeneic hematopoetic stem cell transplantation [PDF]

Expert Opinion on Biological Therapy, 2011
With the use of reduced-intensity conditioning (RIC), early toxicity of allogeneic stem cell transplantation (SCT) has been much reduced. Graft-versus-host disease (GvHD) causes morbidities and mortality. Alemtuzumab is a mAb directed against CD52. When administered prior to transplant, it leads to T-cell depletion.
Xavier Poire, Koen Van Besien
exaly   +3 more sources

"The antibiotic paradox" in allogeneic stem cell transplantation. [PDF]

Bone Marrow Transplant
No abstract available.
Weber D, Meedt E, Ghimire S, Hiergeist A, Kern MAG, Höpting M, Thiele Orberg E, Shaikh H, Beilhack A, Wolff D, Edinger M, Herr W, Gessner A, Poeck H, Holler E.   +14 more
europepmc   +5 more sources

Allogeneic Stem Cell Transplantation in Myelofibrosis [PDF]

Biology of Blood and Marrow Transplantation, 2017
Myeloproliferative neoplasm (MPN) is a category in the World Health Organization classification of myeloid tumors. BCR-ABL1-negative MPN is a subcategory that includes primary myelofibrosis (MF), post-essential thrombocythemia MF, and post-polycythemia vera MF. These disorders are characterized by stem cell-derived clonal myeloproliferation. Clinically,
Tania, Jain, Ruben A, Mesa, Jeanne M, Palmer   +2 more
openaire   +2 more sources

Allogeneic stem cell transplantation for neuroblastoma [PDF]

The Korean Journal of Hematology, 2012
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Although the prognosis of lowand intermediate-risk NB with conventional treatment modalities is excellent, the prognosis of high-risk NB with conventional treatment alone is very poor. The current standard treatment for high-risk NB consists of induction treatment (conventional
openaire   +2 more sources

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis [PDF]

Therapeutic Advances in Hematology, 2020
Myelofibrosis is one of the Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms with heterogeneous clinical course. Though many treatment options, including Janus kinase (JAK) inhibitors, have provided clinical benefits and improved survival, allogeneic hematopoietic stem-cell transplantation (AHSCT) remains the only potentially curative
Lining Zhang, Fan Yang, Sizhou Feng
openaire   +3 more sources

Costs of allogeneic hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation, 2006
This study aims to determine the total costs after allogeneic hematopoietic stem cell transplantation (ASCT) and factors associated with increases or decreases in costs.We collected all in- and outpatient costs during 5 years in 93 patients who had undergone ASCT in 1998 and 1999 at our unit.
Svahn, B.-M.B.M.S., Alvin, O.O.A., Ringden, O.O.R., Gardulf, A.A.G., Remberger, M.M.R.   +4 more
openaire   +2 more sources

Allogeneic hematopoietic stem cell transplantation in Tunisia [PDF]

Bone Marrow Transplantation, 2008
In 1998, the Tunisian team of the 'Centre National de Greffe de Moelle Osseuse' initiated allogeneic hematopoietic SCT (AHSCT) in Tunisia. As of June 2007, information was collected about 299 patients with a first AHSCT and 12 additional retransplants. The median age was 19 years (range 2-49 years). The main indications were aplastic anemia (n=106, 36%)
T, Ben Othman, L, Torjemane, A, Abdelkefi, A, Lakhal, S, Ladeb, L, Ben Hamed, H, Slama, A, Ben Abdeladhim   +7 more
openaire   +2 more sources

Donation and transplantation of allogeneic hematopoietic stem cells [PDF]

Canadian Medical Association Journal, 2011
Only 30% of patients with indications for a transplant have a matched related donor; the remaining 70% seek an unrelated donor on the world’s registry. Nonwhite Canadians have a particularly low likelihood of finding a match.1,2 Appendix 1 lists common indications for transplant (available at ...
Ilana, Kopolovic, Robert, Turner
openaire   +2 more sources

Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012 [PDF]

British Journal of Haematology, 2012
SummaryMyelofibrosis (MF) is a heterogeneous disease for which long‐term, effective medical therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell transplant (AHSCT) in this population, many of whom are elderly, often provides a challenge with regard to the identification of suitable candidates, timing of ...
McLornan, Donal, Mead, Adam J., Jackson, Graham, Harrison, Claire   +3 more
openaire   +5 more sources

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation [PDF]

Journal of Hematotherapy & Stem Cell Research, 2002
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most effective treatment for selected hematological malignancies. Its curative potential is largely mediated by an immune-mediated destruction of malignant cells by donor lymphocytes termed graft-versus-leukemia (GVL) effect.
Baron, Frédéric, Beguin, Yves
openaire   +3 more sources